Rutgers Cancer Institute of New Jersey Experts Available for Comment on Research Topics during National Cancer Research Month
New Brunswick, N.J., April 29, 2021 – Many years of research devoted to cancer has…
New Brunswick, N.J., April 29, 2021 – Many years of research devoted to cancer has…
In a recent JAMA publication, researchers predict, “For the age group 20-49, colorectal cancer was…
Rutgers Cancer Institute has received a $1.3 million, five-year grant from the National Cancer Institute to support the Cancer Metabolism and Growth and Tumor Host Interactions Training Program which will provide postdoctoral candidates the highest quality training and research experience.
SEATTLE — April 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news. April is National Minority Health Month, with a focus on the disproportionate impacts of COVID-19 on communities of color. See more details below on related Fred Hutch programming.Save the date for our monthly public science event, “Science Says” on Tuesday, April 27.
New UCLA study shows that image guided needle based thermal ablation is a safe and effective approach for patients with localized metastatic gynecologic cancers throughout the body.
Deputy director, chief scientific officer, and associate director for Basic Research at Rutgers Cancer Institute of New Jersey has been elected to the 2021 class of Fellows of the American Association for Cancer Research (AACR) Academy, a prestigious accolade offered only to individuals whose work has had a significant and enduring impact on cancer research.
Researchers at the Pritzker School of Molecular Engineering at the University of Chicago have developed a new therapeutic vaccine that uses a patient’s own tumor cells to train their immune system to find and kill cancer.
The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice.
Recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.
Mayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment. The technique is called LEAP, an acronym for “biologically enhanced particle therapy.” The findings are published today in Cancer Research, the journal of the American Association for Cancer Research.
A research team headed by Roswell Park Comprehensive Cancer Center epidemiologist Zhihong Gong, PhD, has been awarded a five-year, $1.9 million grant from the National Cancer Institute for an investigation into the role that certain genetic molecules play in breast cancer disparities.
Scientists are hoping advances in cancer research could lead to a day when a patient’s own immune system could be used to fight and destroy a wide range of tumors. Cancer immunotherapy has some remarkable successes, but its effectiveness has been limited to a relatively small handful of cancers. In APL Bioengineering, researchers describe how advances in engineering models of tumors can greatly expand cancer immunotherapy’s effectiveness to a wider range of cancers.
Sanford Burnham Prebys Medical Discovery Institute has named renowned cancer researcher Ze’ev Ronai, Ph.D., director of its National Cancer Institute (NCI)-designated Cancer Center.
An all-star lineup of basketball greats, several of whom are courageous cancer survivors, will share their stories Feb. 4 at The University of Texas MD Anderson Cancer Center’s A Conversation with a Living Legend event. Robin Roberts, an anchor of “Good Morning America,” will join Emmy Award-winning sportscaster Ernie Johnson Jr. for a virtual fireside chat with a special guest appearance by 11-time NBA All-Star Charles Barkley.
Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.
Henry Ford Health System today announced a $16 million gift to its Henry Ford Pancreatic Cancer Center (HFPCC), which was launched in 2018 by an initial $20 million gift from the same donor, who wishes to remain anonymous. The gift will bolster the HFPCC’s clinical and translational research endeavors in the fight against this devastating disease, for which the five-year survival rate is only 9 percent.
Researchers from The University of Kansas Cancer Center are involved in the presentation of nearly 50 research studies at the 62nd American Society of Hematology (ASH) Annual Meeting.
A team of physicists and biologists investigate the effect that the geometry of the biological environment has on cellular movement. Their findings are published in the journal Science.
The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting The University of Texas
MD Anderson Cancer Center. The 31st annual event honored Admiral William H. McRaven, U.S. Navy, Retired, in an interview Nov. 16 with CBS News’ Bob Schieffer. Proceeds will benefit MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive. A team of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to disrupt that dynamic so that cancer treatments can be more effective. Their latest work, published today in Clinical Cancer Research, a journal of the American Association for Cancer Research, suggests that a drug widely prescribed to control blood pressure may improve patients’ response to cancer immunotherapy.
A phase III trial from India shows that an advanced radiation therapy technique leads to fewer gastrointestinal side effects in women who receive radiation after undergoing hysterectomy for cervical cancer. Findings from the PARCER trial (NCT01279135) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the case for radiation therapy as a treatment for cancer that has begun to spread throughout the body. Findings of the SAFRON II trial (NCT01965223) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Results of a new randomized phase III trial suggest that stereotactic radiosurgery (SRS) should replace whole brain radiation therapy (WBRT) as the standard of care for patients with four or more brain metastases. Results from the clinical trial (NCT01592968) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Adding the advanced PET radiotracer fluciclovine to conventional imaging to help guide radiation treatments for recurrent prostate cancer can improve disease-free survival rates, a new study finds. Findings from the randomized phase II/III EMPIRE-1 trial (NCT01666808) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Our DNA acts like a book of recipes for making proteins. But if a recipe is wrong, what does a cell do Peng Mao, PhD, and his team discovered an intricate series of events that cells use to repair our DNA as the recipes are being read. Their findings could lead to improved cancer treatments.
Dr. Antoni Ribas, a world-renowned physician–scientist and professor of medicine at the David Geffen School of Medicine at UCLA, has been named to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.
After more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer Research Center have moved into their new labs at the newly renovated Lake Union Steam Plant.
The American Society for Radiation Oncology (ASTRO) announced today the press program for its 2020 Annual Meeting, which will feature studies on cancer treatment advances and discussions of topical issues including COVID-19. Researchers will present their findings via live webcasts on October 26 and 27. Register for press access at www.astro.org/annnualmeetingpress.
The Rutgers Youth Enjoy Science (RUYES) program, funded by the National Cancer Institute, will engage underrepresented minority undergraduate and high school students in cutting-edge cancer research, curriculum support, and professional development activities.
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.
September is Blood Cancer Awareness Month and the CU Cancer Center has a patient, Siri Lindley,…
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational treatments for patients with a variety of cancer types.
Announcement of landmark $126 million gift from an extremely generous donor who wishes to remain anonymous. This is the largest single gift in the history of the University of Miami and is in honor of Sylvester’s director Stephen D. Nimer.
Digital cancer registries collect, manage, and store data on cancer patients to help identify trends in diagnoses and treatment. However, cancer pathology reports are complex. To better leverage data, scientists developed an artificial intelligence-based natural language processing tool to help extract information from textual pathology reports.
Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the journal Cancer Research by investigators at the GW Cancer Center.
Britta Will, Ph.D., assistant professor of medicine and of cell biology at Albert Einstein College of Medicine, has won a 2020 Pershing Square Sohn Prize for Young Investigators in Cancer Research. Dr. Will is one of seven New York City area-based scientists to receive the prestigious award, which provides $600,000 over three years for innovative basic science cancer research.
Chuck Wiggins, PhD, Director of the New Mexico Tumor Registry, was recently honored by the North American Association of Central Cancer Registries with its Calum S. Muir Memorial Award.
The discovery of the oncogene responsible for glioblastoma could be the brain tumor’s Achilles’ heel, one researcher says.
Markus Müschen, M.D., Ph.D., has been named the inaugural Director of the Center of Molecular and Cellular Oncology at Yale Cancer Center and Smilow Cancer Hospital. Müschen will also be appointed Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology at Yale School of Medicine.
It is with great pleasure that Ludwig Cancer Research announces the appointment of Yang Shi as Member of the Oxford Branch of the Ludwig Institute for Cancer Research.
USC Norris Comprehensive Cancer Center receives $5 million for cancer drug discoveries
An innovative use of focused ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and could prove useful against other difficult-to-treat cancers.
Atlantic Health System Cancer Care will continue its tradition of world-class medical education with its 2020 Annual Review in Oncology Virtual Symposium. The symposium, held virtually this year with free registration, will take place Saturday, June 27, 2020, from 8 a.m. to 12:30 p.m. ET. Distinguished faculty from some of the Northeast’s leading cancer centers will summarize the latest advances in oncology, which have recently been presented at international conferences. The diverse range of topics should be of interest to surgeons, medical and radiation oncologists and other physicians, nurses and allied health professionals.
Some people must make the difficult decision whether to put food on the table or spend money on other necessities, such as a utility bill or rent. In a recently published paper, Jean McDougall, PhD, and colleagues report the results of a 400-person survey that assesses food insecurity before and after cancer diagnosis
The Memorial Sloan Kettering – Hackensack Meridian Health Partnership has formed an Immunology Research Collaboration, through which researchers can apply for funding to support innovative investigations to explore the power of the immune system and ways it may be harnessed to fight cancer. Three researchers’ projects were selected in 2020 for funding support.
“Senotherapy,” a treatment that uses small molecule drugs to target “senescent” cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute. The study was published in Nature Cell Biology.
NCCN and the NCCN Foundation announce five new recipients for the 10th annual NCCN Foundation Young Investigator Awards (YIA) Program, overseen by the NCCN Oncology Research Program (ORP)
How can researchers and oncologists glean meaningful information from mounds of data to help guide cancer research and patient care? A new analytic tool developed by University of Michigan Rogel Cancer Center researchers combines multiple data sets to help sift the signal from the noise.
David Peabody, PhD, and Bryce Chackerian, PhD, are creating vaccines from particles that are the opposite of Trojan Horses: they look deadly on the outside but are harmless on the inside. Their virus-like particles may rouse the immune system into combatting COVID-19. The idea is to trick the body into believing it’s been infected with a microscopic foe.
The David and Etta Jonas Center for Cellular Therapy is being established at the University of Chicago Medicine to accelerate research in hard-to-treat cancers.